ETC
GLUE icon

Exchange Traded Concepts’s Monte Rosa Therapeutics GLUE Stock Holding History

Exchange Traded Concepts’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,928
Closed -$87.8K – 1445
2025
Q1 		$87.8K Sell
18,928
-10,870
-36% -$66.7K ﹤0.01% 1193
2024
Q4 		$207K Hold
29,798
– – ﹤0.01% 981
2024
Q3 		$158K Sell
29,798
-5,888
-16% -$29.7K ﹤0.01% 1049
2024
Q2 		$133K Sell
35,686
-11,101
-24% -$56.6K ﹤0.01% 920
2024
Q1 		$330K Buy
46,787
+23,460
+101% +$139K 0.01% 769
2023
Q4 		$132K Buy
23,327
+5,915
+34% +$23.2K ﹤0.01% 849
2023
Q3 		$83.4K Sell
17,412
-3,584
-17% -$23.1K ﹤0.01% 957
2023
Q2 		$144K Buy
+20,996
New +$136K ﹤0.01% 850

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Exchange Traded Concepts's GLUE Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 18,928 shares — an estimated $87.8K sold.

Exchange Traded Concepts first reported a position in GLUE in Q2 2023 and held it in 8 quarters. The position peaked at $330K in Q1 2024. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 18,928 Monte Rosa Therapeutics shares in Q2 2025, an estimated $87.8K.
  • Exchange Traded Concepts first reported a position in Monte Rosa Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Monte Rosa Therapeutics position peaked at $330K in Q1 2024.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.